Patent on Hep C drug rejected in Ukraine: Price of sofosbuvir will significantly reduce
The Ministry of Economic Development and Trade of Ukraine (MEDT) refused to grant the pharmaceutical company Gilead a patent for...
Fundación GEP opposes patent on HIV drug Tenofovir (TAF) in Argentina
Pharmaceutical patent would block access to HIV medicines. Our partner is opposing the patent application in a bid to make...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
IP and access to medicines: welcome speech
Our inaugural Global Summit on Intellectual Property and Access to Medicines has started today. Read Solange Baptiste’s welcoming speech below,...
Pathways to Access: Our global summit on intellectual property and access to medicines
23 years after the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement was signed in Morocco, our inaugural conference...
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
‘Questionable’ patent on key HIV drug is challenged in Brazil
Legal challenge essential to prevent further barriers to optimal HIV treatment in Brazil. ABIA, our campaign partner in Brazil, is...
HIV activists trained on intellectual property and access to medicines
Demystifying intellectual property (IP) and providing advocacy tools. The International Treatment Preparedness Coalition – MENA (ITPC-MENA) with the support...